

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



CSPC

CSPC PHARMACEUTICAL GROUP LIMITED

石藥集團有限公司

(Incorporated in Hong Kong with limited liability)

(Stock Code: 1093)

VOLUNTARY ANNOUNCEMENT

**DRUG REGISTRATION APPROVAL OF
THE GROUP'S "SUNITINIB MALATE CAPSULES"**

The board of directors (the "**Board**") of CSPC Pharmaceutical Group Limited (the "**Company**", together with its subsidiaries, the "**Group**") is pleased to announce that "Sunitinib Malate Capsules (12.5mg)" (the "**Product**") developed by CSPC Ouyi Pharmaceutical Co., Ltd.* (石藥集團歐意藥業有限公司), a subsidiary of the Company, has been granted drug registration approval by the National Medical Products Administration of the People's Republic of China, being the first generic drug of this type approved in China.

Sunitinib Malate is an oncology drug indicated for the treatment of 1) inoperable advanced renal cell carcinoma (RCC); 2) gastrointestinal stromal tumor (GIST) after failure of or intolerance to imatinib mesylate treatment; and 3) progressive, well-differentiated pancreatic neuroendocrine tumor (pNET) in adult patients with unresectable or metastatic disease.

The approval of the Product further enriches the product portfolio of the Group and contributes to the Group's development in the oncology field.

By Order of the Board
CSPC Pharmaceutical Group Limited
Cai Dongchen
Chairman

Hong Kong, 2 January 2020

* *For identification purpose only*

As at the date of this announcement, the Board comprises Mr. CAI Dongchen, Mr. ZHANG Cuilong, Mr. WANG Zhenguo, Mr. PAN Weidong, Mr. WANG Huaiyu, Dr. LU Hua, Dr. LI Chunlei, Dr. WANG Qingxi and Mr. CHAK Kin Man as executive directors; Mr. LEE Ka Sze, Carmelo as non-executive director; and Mr. CHAN Siu Keung, Leonard, Mr. WANG Bo, Prof. LO Yuk Lam, Dr. YU Jinming and Mr. CHEN Chuan as independent non-executive directors.